TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3841315
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intrathecal morphine
Study: 3841315
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intrathecal morphine
Study: 26143234
Drug: 4 mm
Normalized name: potassium 8.4 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mm mini-tablet
Study: 26143234
Drug: syrup
Normalized name: Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: syrup
Study: 18507107
Drug: suspension
Normalized name: Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: suspension
Study: 26143234
Drug: joint administration
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: joint administration with food or drink
Study: 23520237
Drug: Weekly telephone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly telephone contact (substudy)
Study: 21878843
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally for up to 12 weeks
Study: 18543496
Drug: Rehabilitation training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation training therapy alone (Control)
Study: 12969104
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion containing ropivacaine (1 mg.ml‐1), fentanyl (2 micro g.ml‐1), and epinephrine (2 micro g.ml‐1) for group RFE.
Study: 12969104
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion without epinephrine for group RF.
Study: 10717247
Drug: 120FEC (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120FEC (120 mg/m2 of epirubicin)
Study: 10717247
Drug: 60FEC (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60FEC (60 mg/m2 of epirubicin)
Study: 9443096
Drug: VPA monotherapy
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA monotherapy
Study: 2868163
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation
Study: 8112200
Drug: DHEP plasters
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEP plasters (diclofenac hydroxyethylpyrrolidine), 180 mg each, applied b.i.d. for 15 days
Study: 3524418
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid (250 mg amoxicillin and 125 mg clavulanic acid) administered every 8 h for 10 days
Study: 3524418
Drug: Cefaclor (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (250 mg) administered every 8 h for 10 days
Study: 26552835
Drug: Noxipoint therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noxipoint therapy (NT)
Study: 26552835
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy including transcutaneous electrical nerve stimulation (PT‐TENS)
Study: 26552835
Drug: NT-like treatments
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-like treatments
Study: 23668887
Drug: DTP booster
Normalized name: DTP-348
DrugBank: DTP-348 (DB12741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP booster vaccine
Study: 20583934
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose methotrexate
Study: 20583934
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose methotrexate
Study: 18218147
Drug: Magnesium treatment
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium treatment (500 mg divided into two tablets for 8 weeks)
Study: 16247548
Drug: Therapeutic education
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic education plus conventional pharmacological treatment
Study: 16247548
Drug: Conventional pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pharmacological treatment only
Study: 14615149
Drug: FSME-IMMUN "new"
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSME-IMMUN "new" vaccine 0.6 microg
Study: 14615149
Drug: FSME-IMMUN "new"
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSME-IMMUN "new" vaccine 1.2 microg
Study: 14615149
Drug: FSME-IMMUN "new"
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSME-IMMUN "new" vaccine 2.4 microg
Study: 8706313
Drug: Pretreatment (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment (before treatment with methimazole)
Study: 8706313
Drug: Treated (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated (after 11.2 ± 1.0 weeks treatment with methimazole)
Study: 8706313
Drug: Propranolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (20 mg thrice daily for 2 days)
Study: 7800160
Drug: Cocaine (60-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (60-80 mg)
Study: 3050587
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Cyclosporin A and Azathioprine)
Study: 29145345
Drug: Other antispastic
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antispastic drug + Lokomat Training
Study: 21159143
Drug: Three courses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three courses of platinum-based chemotherapy
Study: 21159143
Drug: Six courses
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six courses of platinum-based chemotherapy
Study: 21159143
Drug: Chemotherapy use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy use in a national population
Study: 18337042
Drug: Weight-adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-adjusted dose of 1.75 ml/kg
Study: 18337042
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of 120 ml of non-ionic contrast material (320 mg/ml)
Study: 15332395
Drug: OK-432 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 and 30 mg of doxorubicin
Study: 11293552
Drug: Fluvastatin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin XL 80 mg HS
Study: 11293552
Drug: Fluvastatin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin IR 40 mg HS
Study: 2312775
Drug: Metoprolol CR/ZOK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/ZOK 100 mg once daily
Study: 2312775
Drug: Conventional Metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Metoprolol Tablets (CT) 100 mg once daily
Study: 2312775
Drug: Conventional Metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Metoprolol Tablets (CT)
Study: 25231029
Drug: SLActive implants
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLActive implants
Study: 21121960
Drug: SLA implants
Normalized name: slash pine pollen extract
DrugBank: Pinus elliottii pollen (DB10747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLA implants
Study: 26288392
Drug: Grape juice
Normalized name: grape juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape juice (10 mL/(kg·min) for 28 days)
Study: 25138784
Drug: Lornoxicam (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (8 mg)
Study: 12930432
Drug: Tolterodine (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine (twice daily for 16 weeks)
Study: 8697160
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lisinopril
Study: 7039760
Drug: Rosaramicin 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosaramicin 250 mg six hourly for seven days
Study: 7039760
Drug: Tetracycline 250
Normalized name: tetracycline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 250 mg six hourly for seven days
Study: 31456562
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (7 sessions)
Study: 31456562
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (7 sessions)
Study: 29422473
Drug: Preoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative antibiotics at the time of admission
Study: 29422473
Drug: Perioperative antibiotics
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antibiotics at the time of induction of general anesthesia
Study: 27247220
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin/paclitaxel followed by neoadjuvant radiochemotherapy (RCT) to 45 Gy (1.5 Gy twice per day concurrent cisplatin/vinorelbine)
Study: 22963812
Drug: NCX 4016
Normalized name: NCX 701
DrugBank: NCX 701 (DB05409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCX 4016 (800 mg, twice daily)
Study: 20372668
Drug: Tutoring peers
Normalized name: BEER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tutoring peers in oral health (Part 2)
Study: 18357917
Drug: Cytokine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine therapy using colony-stimulating factors (CSF) for bone marrow mobilisation
Study: 18357917
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of monocyte chemoattractant protein 1 (MCP-1)
Study: 18357917
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bone marrow mobilisation and MCP-1 injection
Study: 11711509
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amiloride and spironolactone
Study: 10333091
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (100 mg coenzyme Q10, 600 mg ascorbic acid, 270 mg alpha-tocopherol)
Study: 2268915
Drug: Ginseng‐Rhizome saponin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng‐Rhizome saponin (GRS) 50 mg per tablet, three times a day for two months
Study: 6856487
Drug: Diflunisal 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal 1,000 mg
Study: 3468226
Drug: Propoxyphene napsylate
Normalized name: Propoxyphene Napsylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene napsylate 100 mg
Study: 6856487
Drug: Acetaminophen with
Normalized name: acetaminophen with codeine ORAL ELIXIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen with codeine 60 mg
Study: 6856487
Drug: Propoxyphene with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene with 100 mg
Study: 26955675
Drug: Porous tantalum
Normalized name: tantalum
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porous tantalum rod combined with Gugutou Huaisiyu Capsule (GHC)
Study: 20308663
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of docetaxel, bevacizumab, thalidomide, and prednisone
Study: 12975277
Drug: Radioactive tracer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioactive tracer (10 mCi of technetium 99m‐labeled macroaggregated albumin in 10 mL of physiologic saline)
Study: 3021189
Drug: Aspirin 30
Normalized name: aspirin 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 30 mg
Study: 1745620
Drug: Cefepime 2
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2 g every 12 hours plus metronidazole 500 mg every 6 hours intravenously
Study: 1745620
Drug: Gentamicin 1.5
Normalized name: HYDROCORTISONE ACEPONATE 1.11 mg in 1 mL / MICONAZOLE NITRATE 17.4 mg in 1 mL / GENTAMICIN 1.5 mg in 1 mL AURICULAR (OTIC) SUSPENSION [EASOTIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 1.5 mg/kg plus clindamycin 900 mg every 8 hours intravenously
Study: 17152739
Drug: Ergotamine 1
Normalized name: ergotamine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergotamine 1 mg
Study: 11903083
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg
Study: 17152739
Drug: Ergotamine 1
Normalized name: ergotamine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergotamine 1 mg + Metoclopramide 20 mg
Study: 17152739
Drug: Ergotamine 2
Normalized name: ergotamine 2 mg sublingual tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergotamine 2 mg + Metoclopramide 20 mg
Study: 27116364
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment group (two, 150-minute group sessions spaced one-week apart)
Study: 23163910
Drug: linagliptin 10
Normalized name: empagliflozin-linagliptin 10 mg-5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 10 mg
Study: 22145698
Drug: linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 5 mg, linagliptin 10 mg, placebo, voglibose
Study: 177210
Drug: BCNU (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCNU (100 mg/m2 qd X 1) and procarbazine (100 mg/m2 qd X 14)
Study: 177210
Drug: Previous combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous combination of procarbazine, CCNU, and vincristine
Study: 25924819
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg four times daily (q.i.d.)
Study: 25924819
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg two times a day (b.i.d.)
Study: 21270789
Drug: Buprenorphine (B)
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine (B) 16 mg, n = 18
Study: 21270789
Drug: Buprenorphine/Naloxone (B/N)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/Naloxone (B/N) 16/4 mg, n = 16
Study: 18650507
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of simvastatin daily
Study: 18650507
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of simvastatin daily
Study: 18650507
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified dosage)
Study: 6429852
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg 2% nitroglycerin ointment (Plantorgan Co.)
Study: 6429852
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg 2% nitroglycerin ointment (Pohl Boskamp Co.)
Study: 6429852
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg nitroglycerin in the transdermal therapeutic system (Ciba Geigy)
Study: 30910440
Drug: GSP301 (665
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSP301 (665 μg of olopatadine and 25 μg of mometasone)
Study: 30910440
Drug: Olopatadine (665
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine (665 μg)
Study: 30910440
Drug: Mometasone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone (25 μg)
Study: 29974521
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid (ALA) 600 mg intravenous before graft reperfusion
Study: 29974521
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid (ALA) treatment
Study: 23336412
Drug: Protein-free calf
Normalized name: thymus gland-calf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-free calf blood extract ophthalmic gel
Study: 23336412
Drug: Recombinant bovine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant bovine basic fibroblast growth factor ophthalmic gel
Study: 26907728
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray
Study: 12764120
Drug: Preconditioning with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preconditioning with sumatriptan (5‐HT(1B/1D) agonist) followed by placebo administration
Study: 12764120
Drug: Verbal suggestions
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal suggestions of increase/decrease of growth hormone (GH) and cortisol
Study: 9327315
Drug: Midazolam +
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam + Oral Transmucosal Fentanyl Citrate (OTFC)
Study: 18157519
Drug: UDCA (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (300 mg/day)
Study: 15753414
Drug: Risedronate (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (2.5 mg daily for 12 months)
Study: 12616667
Drug: Commercially prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially prepared oral syrup
Study: 12616667
Drug: Reference capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference capsule formulation
Study: 10546521
Drug: Tamoxifen and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen and/or chemotherapy
Study: 10546521
Drug: New cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New cytotoxic drugs (taxanes, vinorelbine, capecitabine), high dose chemotherapy, immunotherapy with monoclonal antibodies (herceptin), gene therapeutic approaches
Study: 10546521
Drug: Predictive factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive factors and biological markers
Study: 6406616
Drug: Cefazolin prophylaxis
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin prophylaxis (5 doses of 1g)
Study: 23091128
Drug: Group G:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group G: inactivated Lactobacillus salivarius and sodium butyrate
Study: 23091128
Drug: Groups D,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups D, E, and G
Study: 23091128
Drug: Groups E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Groups E and G
Study: 23091128
Drug: Groups B,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups B, C, E, G, and I after d 15
Study: 23091128
Drug: Groups B,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups B, C, D, E, F, G, and H after d 45
Study: 23091128
Drug: Groups F
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups F and G at d 45
Study: 17968180
Drug: Iloprost in
Normalized name: iloprost Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost in saline solution for 3 weeks
Study: 9425969
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 3.4 mL of hypobaric 0.18% bupivacaine (6.12 mg)
Study: 8483561
Drug: Epirubicin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (100 mg/m2)
Study: 8483561
Drug: FEM (5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEM (5-fluorouracil 600 mg/m2, epirubicin 50 mg/m2, mitomycin 6 mg/m2)
Study: 2961394
Drug: Epidural injections
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injections
Study: 26791805
Drug: Testofen (Trigonella
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testofen (Trigonella foenum-graecum seed extract) at a dose of 600 mg/day for 12 weeks
Study: 23216401
Drug: Short-term individual
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term individual dynamic therapy
Study: 23216401
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication (augmented treatment)
Study: 12814316
Drug: HA-coated threaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-coated threaded implants
Study: 12814316
Drug: HA-coated cylindric
Normalized name: Imperata cylindrica root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-coated cylindric implants
Study: 12814316
Drug: machined Ti
Approvals — FDA: no, EMA: no, PMDA: no
Description: machined Ti threaded implants
Study: 9780560
Drug: Antiandrogen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiandrogen therapy combined with radiation therapy
Study: 28170391
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of primaquine (1 mg base/kg/day for 7 days)
Study: 28170391
Drug: Standard high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard high dose of primaquine (0.5 mg base/kg/day for 14 days)
Study: 21616170
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of milled flaxseed per day
Study: 16765760
Drug: Repeat intramuscular
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat intramuscular dose of 11.4 mg betamethasone (as Celestone Chronodose)
Study: 14757602
Drug: Nebulized epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized epinephrine (0.9 mg/kg of 2.25% racemic epinephrine)
Study: 14757602
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (0.15 mg/kg of 0.5% albuterol sulfate)
Study: 2963230
Drug: High-dose leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose leucovorin plus FUra (Arm B)
Study: 2963230
Drug: Sequential methotrexate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential methotrexate, FUra, leucovorin (Arm C)
Study: 22820873
Drug: Waitlist (clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist (clinical treatment as usual)
Study: 21853859
Drug: Amino acid-carbohydrate
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid-carbohydrate (AACHO) prior to resistance exercise (979 kJ, 36 g carbohydrate, 22.5 g protein)